USFDAApr 28, 2026, 08:21 AM
PRFX OcuRing -K IND Cleared for Phase II Clinical Trial
AI Summary
PRF Technologies announced FDA clearance of its Investigational New Drug (IND) application for OcuRing -K, enabling the initiation of a Phase II clinical trial. OcuRing -K is a patent-protected, bio-erodible intraocular ring designed to deliver ketorolac for post-cataract pain and inflammation, aiming to eliminate the need for post-surgical eye drops. This milestone advances the company's ophthalmic drug-delivery strategy, with patient enrollment for the multi-center U.S. Phase II trial expected to begin in the second half of 2026.
Key Highlights
- FDA cleared Investigational New Drug (IND) application for OcuRing -K.
- Enables initiation of a Phase II clinical trial for post-cataract pain and inflammation.
- OcuRing -K is a patent-protected, bio-erodible intraocular ring delivering ketorolac.
- Aims to provide drop-less, sustained-release therapy, simplifying post-operative care.
- Patient enrollment for the multi-center U.S. Phase II trial is expected to begin in H2 2026.
Price Impact
More from PRFX